Obesity drug developer Metsera said Friday that … vast market for weight-loss drugs, having fallen behind Novo Nordisk … triggering a bidding war with Pfizer. Pfizer filed two lawsuits in the … Nov. 13, Metsera and Pfizer said. This article originally appeared …

… the global drug market. The acquisition marks Pfizer’s renewed … push into the fast-growing weight-loss drug … the agreement announced Friday, Pfizer will purchase Metsera for up … had prompted a lawsuit from Pfizer. Pfizer’s final offer — …

Pfizer Inc. agreed to buy Metsera … rival bid for the obesity drug startup. Pfizer raised its offer to …

… called superior. The Danish obesity drug behemoth said on Saturday it … stumbles in developing weight-loss drugs. Pfizer has agreed to pay $86 … cholesterol-lowering drug. “While this is a smaller deal, Pfizer must believe …

… drugs including Ozempic and Wegovy, gatecrashed a takeover deal between Pfizer … of weight-loss drugs in early development. Pfizer planned to … a furious response from Pfizer, which accused the Danish … its board would unanimously recommend Pfizer's offer. …

… gives Pfizer a foothold in the lucrative obesity-drug market, … DRUGS Pfizer has won a $10 billion deal to acquire obesity drug … s future performance, estimating Pfizer would need to generate … shareholders approve the amended Pfizer offer. The biotech currently …

… drugs.  Under terms of a deal announced late Friday, Pfizer … and messy squabble between Pfizer and Novo over an … working on a counterproposal, Pfizer filed two lawsuits against Metsera … later “challenged or rescinded.”  Pfizer’s original bid included an …

NEW YORK – U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy. Metsera, based in New …

… that sales for obesity drugs could escalate significantly, from … the obesity drug segment. The Bidding War Pfizer initiated the … 13. Pipeline of Experimental Drugs Metsera continues to develop … Analysts predict that these drugs could collectively achieve peak …